AU2014292926B2 - Spherical nucleic acid-based constructs as immunostimulatory agents for prophylactic and therapeutic use - Google Patents

Spherical nucleic acid-based constructs as immunostimulatory agents for prophylactic and therapeutic use Download PDF

Info

Publication number
AU2014292926B2
AU2014292926B2 AU2014292926A AU2014292926A AU2014292926B2 AU 2014292926 B2 AU2014292926 B2 AU 2014292926B2 AU 2014292926 A AU2014292926 A AU 2014292926A AU 2014292926 A AU2014292926 A AU 2014292926A AU 2014292926 B2 AU2014292926 B2 AU 2014292926B2
Authority
AU
Australia
Prior art keywords
nucleic acid
nanoscale construct
tlr
nanoscale
construct
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2014292926A
Other languages
English (en)
Other versions
AU2014292926A1 (en
Inventor
Sergei Gryaznov
Warefta HASAN
Aaron Love
Christopher C. Mader
Subbarao NALLAGATLA
Aleksandar Filip Radovic-Moreno
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Exicure Operating Co
Original Assignee
Exicure Operating Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Exicure Operating Co filed Critical Exicure Operating Co
Publication of AU2014292926A1 publication Critical patent/AU2014292926A1/en
Application granted granted Critical
Publication of AU2014292926B2 publication Critical patent/AU2014292926B2/en
Assigned to EXICURE OPERATING COMPANY reassignment EXICURE OPERATING COMPANY Request for Assignment Assignors: EXICURE, INC.
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/17—Immunomodulatory nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/32—Special delivery means, e.g. tissue-specific
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Nanotechnology (AREA)
  • Rheumatology (AREA)
AU2014292926A 2013-07-25 2014-07-25 Spherical nucleic acid-based constructs as immunostimulatory agents for prophylactic and therapeutic use Active AU2014292926B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361858558P 2013-07-25 2013-07-25
US61/858,558 2013-07-25
PCT/US2014/048291 WO2015013673A1 (en) 2013-07-25 2014-07-25 Spherical nucleic acid-based constructs as immunostimulatory agents for prophylactic and therapeutic use

Publications (2)

Publication Number Publication Date
AU2014292926A1 AU2014292926A1 (en) 2016-03-10
AU2014292926B2 true AU2014292926B2 (en) 2020-03-05

Family

ID=51303118

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2014292926A Active AU2014292926B2 (en) 2013-07-25 2014-07-25 Spherical nucleic acid-based constructs as immunostimulatory agents for prophylactic and therapeutic use

Country Status (9)

Country Link
US (4) US10894963B2 (cg-RX-API-DMAC7.html)
EP (1) EP3024936B1 (cg-RX-API-DMAC7.html)
JP (1) JP6697384B2 (cg-RX-API-DMAC7.html)
KR (1) KR20160042917A (cg-RX-API-DMAC7.html)
CN (1) CN105579582A (cg-RX-API-DMAC7.html)
AU (1) AU2014292926B2 (cg-RX-API-DMAC7.html)
CA (1) CA2919268C (cg-RX-API-DMAC7.html)
ES (1) ES2750608T3 (cg-RX-API-DMAC7.html)
WO (1) WO2015013673A1 (cg-RX-API-DMAC7.html)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102282155B (zh) 2008-12-02 2017-06-09 日本波涛生命科学公司 磷原子修饰的核酸的合成方法
US20100233270A1 (en) 2009-01-08 2010-09-16 Northwestern University Delivery of Oligonucleotide-Functionalized Nanoparticles
BR112012000828A8 (pt) 2009-07-06 2017-10-10 Ontorii Inc Novas pró-drogas de ácido nucleico e métodos de uso das mesmas
EP2620428B1 (en) 2010-09-24 2019-05-22 Wave Life Sciences Ltd. Asymmetric auxiliary group
ES2626488T3 (es) 2011-07-19 2017-07-25 Wave Life Sciences Pte. Ltd. Procedimientos para la síntesis de ácidos nucleicos funcionalizados
ES2940887T3 (es) 2012-07-13 2023-05-12 Wave Life Sciences Ltd Método de preparación de oligonucleótidos quirales
ES2862073T3 (es) 2012-07-13 2021-10-06 Wave Life Sciences Ltd Grupo auxiliar asimétrico
BR112015000723A2 (pt) * 2012-07-13 2017-06-27 Shin Nippon Biomedical Laboratories Ltd adjuvante de ácido nucléico quiral
AU2014292926B2 (en) * 2013-07-25 2020-03-05 Exicure Operating Company Spherical nucleic acid-based constructs as immunostimulatory agents for prophylactic and therapeutic use
US10568898B2 (en) 2013-08-13 2020-02-25 Northwestern University Lipophilic nanoparticles for drug delivery
JP6527516B2 (ja) 2013-12-03 2019-06-05 ノースウェスタン ユニバーシティ リポソーム粒子、前述のものを作製する方法及びその使用
WO2015108047A1 (ja) 2014-01-15 2015-07-23 株式会社新日本科学 免疫誘導活性を有するキラル核酸アジュバンド及び免疫誘導活性剤
US10322173B2 (en) 2014-01-15 2019-06-18 Shin Nippon Biomedical Laboratories, Ltd. Chiral nucleic acid adjuvant having anti-allergic activity, and anti-allergic agent
JPWO2015108048A1 (ja) 2014-01-15 2017-03-23 株式会社新日本科学 抗腫瘍作用を有するキラル核酸アジュバンド及び抗腫瘍剤
CN113278617A (zh) 2014-01-16 2021-08-20 波涛生命科学有限公司 手性设计
US10413565B2 (en) 2014-04-30 2019-09-17 Northwestern University Nanostructures for modulating intercellular communication and uses thereof
WO2015187966A1 (en) 2014-06-04 2015-12-10 Aurasense Therapeutics, Llc Multivalent delivery of immune modulators by liposomal spherical nucleic acids for prophylactic or therapeutic applications
WO2016004168A1 (en) * 2014-07-01 2016-01-07 Aurasense Therapeutics, Llc Spherical nanoparticles as antibacterial agents
BR112017007012A2 (pt) 2014-10-06 2018-03-06 Exicure Inc compostos anti-tnf
CA2973702A1 (en) 2015-01-14 2016-07-21 Exicure, Inc. Nucleic acid nanostructures with core motifs
US20180042848A1 (en) * 2015-02-18 2018-02-15 Exicure, Inc. Immuno-regulatory lipid containing spherical nucleic acids
US10078092B2 (en) 2015-03-18 2018-09-18 Northwestern University Assays for measuring binding kinetics and binding capacity of acceptors for lipophilic or amphiphilic molecules
WO2017193087A1 (en) 2016-05-06 2017-11-09 Exicure, Inc. Liposomal spherical nucleic acid (sna) constructs prsenting antisense oligonucleotides(aso) for specific knockdown of interleukin 17 receptor mrna
AU2017261354A1 (en) * 2016-05-06 2018-11-29 Exicure Operating Company Spherical Nucleic Acid TLR9 agonists
CN109831915A (zh) * 2016-05-06 2019-05-31 埃克西奎雷股份有限公司 具有强力抗肿瘤活性的靶向tlr9的球形核酸
US11793874B2 (en) 2017-03-30 2023-10-24 The University Of Kitakyushu Immunity-inducing agent and pharmaceutical composition containing same
WO2018201090A1 (en) 2017-04-28 2018-11-01 Exicure, Inc. Synthesis of spherical nucleic acids using lipophilic moieties
AU2018314159A1 (en) 2017-07-13 2020-01-30 Northwestern University General and direct method for preparing oligonucleotide-functionalized metal-organic framework nanoparticles
JP7023460B2 (ja) * 2017-10-26 2022-02-22 国立大学法人 鹿児島大学 Ｔｌｒリガンド固定化ナノ粒子
WO2019200262A1 (en) * 2018-04-13 2019-10-17 Northwestern University Addressing nanomedicine complexity through novel high-throughput screening and machine learning
WO2019222423A1 (en) * 2018-05-15 2019-11-21 The Brigham And Women's Hospital, Inc. Compositions and methods related to tumor cell killers and vaccines
BR112021005601A2 (pt) * 2018-09-28 2021-06-29 The University Of Kitakyushu indutor de imunidade que compreende conjugado de nucleotídeo de peptídeo adjuvante antigênico e composição farmacêutica que compreende o mesmo
AU2020223028A1 (en) * 2019-02-12 2021-09-23 Exicure Operating Company Combined spherical nucleic acid and checkpoint inhibitor for antitumor therapy
CN109701008B (zh) * 2019-02-18 2022-06-21 山东兴瑞生物科技有限公司 针对单纯疱疹病毒的治疗性dc复合疫苗及其制备方法
WO2021040439A1 (ko) * 2019-08-28 2021-03-04 주식회사 엔에이백신연구소 신규한 핵산을 기반으로 하는 인플루엔자 백신 조성물
US12319711B2 (en) 2019-09-20 2025-06-03 Northwestern University Spherical nucleic acids with tailored and active protein coronae
US12378560B2 (en) 2019-10-29 2025-08-05 Northwestern University Sequence multiplicity within spherical nucleic acids
US20210220454A1 (en) * 2020-01-22 2021-07-22 Northwestern University Design of immunostimulatory protein-core spherical nucleic acids
CA3190428A1 (en) * 2020-07-31 2022-02-03 The Board Of Trustees Of The Leland Stanford Junior University Vaccine compositions and methods of use thereof
EP4104830A1 (en) 2021-06-16 2022-12-21 Burghardt Wittig Sequential innate and adaptive immune modulation for cancer treatment
US20250354140A1 (en) * 2022-05-05 2025-11-20 Northwestern University Calcium salted spherical nucleic acids
KR20240138659A (ko) * 2023-03-10 2024-09-20 서울시립대학교 산학협력단 DNA-Au 구조체 및 그 제조방법

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120282186A1 (en) * 2009-10-30 2012-11-08 Northwestern University Templated nanoconjugates

Family Cites Families (334)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4489055A (en) 1978-07-19 1984-12-18 N.V. Sopar S.A. Process for preparing biodegradable submicroscopic particles containing a biologically active substance and their use
US4289872A (en) 1979-04-06 1981-09-15 Allied Corporation Macromolecular highly branched homogeneous compound based on lysine units
US4469863A (en) 1980-11-12 1984-09-04 Ts O Paul O P Nonionic nucleic acid alkyl and aryl phosphonates and processes for manufacture and use thereof
US5008050A (en) 1984-06-20 1991-04-16 The Liposome Company, Inc. Extrusion technique for producing unilamellar vesicles
US5166315A (en) 1989-12-20 1992-11-24 Anti-Gene Development Group Sequence-specific binding polymers for duplex nucleic acids
US5264423A (en) 1987-03-25 1993-11-23 The United States Of America As Represented By The Department Of Health And Human Services Inhibitors for replication of retroviruses and for the expression of oncogene products
US5276019A (en) 1987-03-25 1994-01-04 The United States Of America As Represented By The Department Of Health And Human Services Inhibitors for replication of retroviruses and for the expression of oncogene products
US5229490A (en) 1987-05-06 1993-07-20 The Rockefeller University Multiple antigen peptide system
US4904582A (en) 1987-06-11 1990-02-27 Synthetic Genetics Novel amphiphilic nucleic acid conjugates
CA1340032C (en) 1987-06-24 1998-09-08 Jim Haralambidis Lucleoside derivatives
US4924624A (en) 1987-10-22 1990-05-15 Temple University-Of The Commonwealth System Of Higher Education 2,',5'-phosphorothioate oligoadenylates and plant antiviral uses thereof
US5188897A (en) 1987-10-22 1993-02-23 Temple University Of The Commonwealth System Of Higher Education Encapsulated 2',5'-phosphorothioate oligoadenylates
EP0406309A4 (en) 1988-03-25 1992-08-19 The University Of Virginia Alumni Patents Foundation Oligonucleotide n-alkylphosphoramidates
US5216141A (en) 1988-06-06 1993-06-01 Benner Steven A Oligonucleotide analogs containing sulfur linkages
US5457183A (en) 1989-03-06 1995-10-10 Board Of Regents, The University Of Texas System Hydroxylated texaphyrins
US5256775A (en) 1989-06-05 1993-10-26 Gilead Sciences, Inc. Exonuclease-resistant oligonucleotides
US4958013A (en) 1989-06-06 1990-09-18 Northwestern University Cholesteryl modified oligonucleotides
US5134066A (en) 1989-08-29 1992-07-28 Monsanto Company Improved probes using nucleosides containing 3-dezauracil analogs
US5591722A (en) 1989-09-15 1997-01-07 Southern Research Institute 2'-deoxy-4'-thioribonucleosides and their antiviral activity
US5399676A (en) 1989-10-23 1995-03-21 Gilead Sciences Oligonucleotides with inverted polarity
JPH05504552A (ja) 1989-10-24 1993-07-15 ギリアド　サイエンシズ，インコーポレイテッド ２’位が改変されたオリゴヌクレオチド
US5177198A (en) 1989-11-30 1993-01-05 University Of N.C. At Chapel Hill Process for preparing oligoribonucleoside and oligodeoxyribonucleoside boranophosphates
US5578718A (en) 1990-01-11 1996-11-26 Isis Pharmaceuticals, Inc. Thiol-derivatized nucleosides
US5955589A (en) 1991-12-24 1999-09-21 Isis Pharmaceuticals Inc. Gapped 2' modified oligonucleotides
US5587361A (en) 1991-10-15 1996-12-24 Isis Pharmaceuticals, Inc. Oligonucleotides having phosphorothioate linkages of high chiral purity
US5264618A (en) 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
US5618704A (en) 1990-07-27 1997-04-08 Isis Pharmacueticals, Inc. Backbone-modified oligonucleotide analogs and preparation thereof through radical coupling
US5610289A (en) 1990-07-27 1997-03-11 Isis Pharmaceuticals, Inc. Backbone modified oligonucleotide analogues
US5541307A (en) 1990-07-27 1996-07-30 Isis Pharmaceuticals, Inc. Backbone modified oligonucleotide analogs and solid phase synthesis thereof
US5677437A (en) 1990-07-27 1997-10-14 Isis Pharmaceuticals, Inc. Heteroatomic oligonucleoside linkages
US5489677A (en) 1990-07-27 1996-02-06 Isis Pharmaceuticals, Inc. Oligonucleoside linkages containing adjacent oxygen and nitrogen atoms
US5608046A (en) 1990-07-27 1997-03-04 Isis Pharmaceuticals, Inc. Conjugated 4'-desmethyl nucleoside analog compounds
US5623070A (en) 1990-07-27 1997-04-22 Isis Pharmaceuticals, Inc. Heteroatomic oligonucleoside linkages
US5602240A (en) 1990-07-27 1997-02-11 Ciba Geigy Ag. Backbone modified oligonucleotide analogs
US5138045A (en) 1990-07-27 1992-08-11 Isis Pharmaceuticals Polyamine conjugated oligonucleotides
FI930455A7 (fi) 1990-08-03 1993-03-24 Sanofi Sa Yhdisteitä ja menetelmiä geeniekspression inhiboimiseksi
US5177196A (en) 1990-08-16 1993-01-05 Microprobe Corporation Oligo (α-arabinofuranosyl nucleotides) and α-arabinofuranosyl precursors thereof
FR2677272B1 (fr) 1991-06-05 1995-03-03 Biovecteurs As Vecteur particulaire a tropisme selectif, procede de preparation et composition pharmaceutique.
US5594121A (en) 1991-11-07 1997-01-14 Gilead Sciences, Inc. Enhanced triple-helix and double-helix formation with oligomers containing modified purines
US5484908A (en) 1991-11-26 1996-01-16 Gilead Sciences, Inc. Oligonucleotides containing 5-propynyl pyrimidines
US5792608A (en) 1991-12-12 1998-08-11 Gilead Sciences, Inc. Nuclease stable and binding competent oligomers and methods for their use
US5359044A (en) 1991-12-13 1994-10-25 Isis Pharmaceuticals Cyclobutyl oligonucleotide surrogates
US5700922A (en) 1991-12-24 1997-12-23 Isis Pharmaceuticals, Inc. PNA-DNA-PNA chimeric macromolecules
FR2687679B1 (fr) 1992-02-05 1994-10-28 Centre Nat Rech Scient Oligothionucleotides.
US5814666A (en) 1992-04-13 1998-09-29 The United States As Represented By The Department Of Health And Human Services Encapsulated and non-encapsulated nitric oxide generators used as antimicrobial agents
US5633360A (en) 1992-04-14 1997-05-27 Gilead Sciences, Inc. Oligonucleotide analogs capable of passive cell membrane permeation
JPH07508342A (ja) 1992-04-22 1995-09-14 エコール ポリテクニーク フェデラル ドゥ ローザンヌ（エーペーエフエル） 脂質膜センサー
US5434257A (en) 1992-06-01 1995-07-18 Gilead Sciences, Inc. Binding compentent oligomers containing unsaturated 3',5' and 2',5' linkages
US5472881A (en) 1992-11-12 1995-12-05 University Of Utah Research Foundation Thiol labeling of DNA for attachment to gold surfaces
EP0691968B1 (en) 1993-03-30 1997-07-16 Sanofi Acyclic nucleoside analogs and oligonucleotide sequences containing them
EP0691977B1 (en) 1993-03-31 1997-11-26 Sanofi Oligonucleotides with amide linkages replacing phosphodiester linkages
US5457187A (en) 1993-12-08 1995-10-10 Board Of Regents University Of Nebraska Oligonucleotides containing 5-fluorouracil
US5519134A (en) 1994-01-11 1996-05-21 Isis Pharmaceuticals, Inc. Pyrrolidine-containing monomers and oligomers
US5596091A (en) 1994-03-18 1997-01-21 The Regents Of The University Of California Antisense oligonucleotides comprising 5-aminoalkyl pyrimidine nucleotides
US5627053A (en) 1994-03-29 1997-05-06 Ribozyme Pharmaceuticals, Inc. 2'deoxy-2'-alkylnucleotide containing nucleic acid
US5646269A (en) 1994-04-28 1997-07-08 Gilead Sciences, Inc. Method for oligonucleotide analog synthesis
US20030026782A1 (en) 1995-02-07 2003-02-06 Arthur M. Krieg Immunomodulatory oligonucleotides
US6239116B1 (en) 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
CA2560114A1 (en) 1994-07-15 1996-02-01 The University Of Iowa Research Foundation Immunomodulatory oligonucleotides
EP0824541B1 (en) 1995-05-04 2009-12-16 Gilead Sciences, Inc. Nucleic acid ligand complexes
US5912340A (en) 1995-10-04 1999-06-15 Epoch Pharmaceuticals, Inc. Selective binding complementary oligonucleotides
US5780448A (en) 1995-11-07 1998-07-14 Ottawa Civic Hospital Loeb Research DNA-based vaccination of fish
US6506564B1 (en) 1996-07-29 2003-01-14 Nanosphere, Inc. Nanoparticles having oligonucleotides attached thereto and uses therefor
US6582921B2 (en) 1996-07-29 2003-06-24 Nanosphere, Inc. Nanoparticles having oligonucleotides attached thereto and uses thereof
US6361944B1 (en) 1996-07-29 2002-03-26 Nanosphere, Inc. Nanoparticles having oligonucleotides attached thereto and uses therefor
US6056973A (en) 1996-10-11 2000-05-02 Sequus Pharmaceuticals, Inc. Therapeutic liposome composition and method of preparation
US6051698A (en) 1997-06-06 2000-04-18 Janjic; Nebojsa Vascular endothelial growth factor (VEGF) nucleic acid ligand complexes
US20060002949A1 (en) 1996-11-14 2006-01-05 Army Govt. Of The Usa, As Rep. By Secretary Of The Office Of The Command Judge Advocate, Hq Usamrmc. Transcutaneous immunization without heterologous adjuvant
US6406705B1 (en) 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
EP0985033A4 (en) 1997-04-04 2005-07-13 Biosite Inc POLYVALENT AND POLYCLONAL LIBRARIES
US20030104044A1 (en) 1997-05-14 2003-06-05 Semple Sean C. Compositions for stimulating cytokine secretion and inducing an immune response
DE69841002D1 (de) 1997-05-14 2009-09-03 Univ British Columbia Hochwirksame verkapselung von nukleinsäuren in lipidvesikeln
US6271209B1 (en) 1998-04-03 2001-08-07 Valentis, Inc. Cationic lipid formulation delivering nucleic acid to peritoneal tumors
US6287765B1 (en) 1998-05-20 2001-09-11 Molecular Machines, Inc. Methods for detecting and identifying single molecules
SI1077722T1 (sl) 1998-05-22 2007-02-28 Ottawa Health Research Inst Metode in produkti za induciranje sluznicne imunosti
US6562798B1 (en) 1998-06-05 2003-05-13 Dynavax Technologies Corp. Immunostimulatory oligonucleotides with modified bases and methods of use thereof
FR2783170B1 (fr) 1998-09-11 2004-07-16 Pasteur Merieux Serums Vacc Emulsion immunostimulante
US6080580A (en) 1998-10-05 2000-06-27 Isis Pharmaceuticals Inc. Antisense oligonucleotide modulation of tumor necrosis factor-α (TNF-α) expression
US6228642B1 (en) 1998-10-05 2001-05-08 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of tumor necrosis factor-(α) (TNF-α) expression
AR022404A1 (es) 1999-01-25 2002-09-04 Photogen Inc Metodo y agentes para la terapia de radiacion mejorada
CA2376623C (en) 1999-06-25 2011-04-19 Nanosphere, Inc. Nanoparticles having oligonucleotides attached thereto and uses therefor
WO2001003709A1 (en) 1999-07-08 2001-01-18 Cap Biotechnology, Inc. Calcium-containing structures and methods of making and using the same
EP1072679A3 (en) 1999-07-20 2002-07-31 Agilent Technologies, Inc. (a Delaware corporation) Method of producing nucleic acid molecules with reduced secondary structure
DE19935756A1 (de) 1999-07-27 2001-02-08 Mologen Forschungs Entwicklung Kovalent geschlossenes Nukleinsäuremolekül zur Immunstimulation
CA2380947C (en) 1999-08-19 2011-11-01 Dynavax Technologies Corporation Methods of modulating an immune response using immunostimulatory sequences and compositions for use therein
US20050249794A1 (en) 1999-08-27 2005-11-10 Semple Sean C Compositions for stimulating cytokine secretion and inducing an immune response
WO2001022972A2 (en) 1999-09-25 2001-04-05 University Of Iowa Research Foundation Immunostimulatory nucleic acids
US6949520B1 (en) 1999-09-27 2005-09-27 Coley Pharmaceutical Group, Inc. Methods related to immunostimulatory nucleic acid-induced interferon
US6585947B1 (en) 1999-10-22 2003-07-01 The Board Of Trustess Of The University Of Illinois Method for producing silicon nanoparticles
US7223398B1 (en) 1999-11-15 2007-05-29 Dynavax Technologies Corporation Immunomodulatory compositions containing an immunostimulatory sequence linked to antigen and methods of use thereof
ATE393221T1 (de) 1999-11-29 2008-05-15 Avi Biopharma Inc Gegen bakterielle 16s und 23s rrnas gerichtete ungeladene antisense oligonukleotide und deren verwendungen
CA2395742A1 (fr) 1999-12-30 2001-07-12 Aventis Pharma S.A. Compositions comprenant des acides nucleiques incorpores dans des particules minerales bilamellaires
AT409085B (de) 2000-01-28 2002-05-27 Cistem Biotechnologies Gmbh Pharmazeutische zusammensetzung zur immunmodulation und herstellung von vakzinen
US7833992B2 (en) 2001-05-18 2010-11-16 Merck Sharpe & Dohme Conjugates and compositions for cellular delivery
US20020156033A1 (en) 2000-03-03 2002-10-24 Bratzler Robert L. Immunostimulatory nucleic acids and cancer medicament combination therapy for the treatment of cancer
US20040131628A1 (en) 2000-03-08 2004-07-08 Bratzler Robert L. Nucleic acids for the treatment of disorders associated with microorganisms
US7129222B2 (en) 2000-03-10 2006-10-31 Dynavax Technologies Corporation Immunomodulatory formulations and methods for use thereof
US20030129251A1 (en) 2000-03-10 2003-07-10 Gary Van Nest Biodegradable immunomodulatory formulations and methods for use thereof
US6534062B2 (en) 2000-03-28 2003-03-18 The Regents Of The University Of California Methods for increasing a cytotoxic T lymphocyte response in vivo
US7291284B2 (en) 2000-05-26 2007-11-06 Northwestern University Fabrication of sub-50 nm solid-state nanostructures based on nanolithography
AU2001276870B2 (en) 2000-07-11 2006-07-20 Northwestern University Method of detection by enhancement of silver staining
US7083958B2 (en) 2000-11-20 2006-08-01 The Board Of Trustees Of The University Of Illinois Membrane scaffold proteins
US7563618B2 (en) 2001-03-23 2009-07-21 Geron Corporation Oligonucleotide conjugates
GB0111279D0 (en) 2001-05-10 2001-06-27 Nycomed Imaging As Radiolabelled liposomes
US7238472B2 (en) 2001-05-25 2007-07-03 Nanosphere, Inc. Non-alloying core shell nanoparticles
MXPA03010893A (es) 2001-05-30 2004-10-28 Univ Leland Stanford Junior Sistema de suministro para acidos nucleicos.
CN100334228C (zh) 2001-06-21 2007-08-29 戴纳瓦克斯技术公司 嵌合免疫调制化合物及其使用方法
CA2453417A1 (en) 2001-07-10 2003-06-26 North Carolina State University Nanoparticle delivery vehicle
US7666674B2 (en) 2001-07-27 2010-02-23 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Use of sterically stabilized cationic liposomes to efficiently deliver CPG oligonucleotides in vivo
JP4607452B2 (ja) 2001-08-07 2011-01-05 ダイナバックス テクノロジーズ コーポレイション 免疫調節性組成物、製剤およびその使用方法
AU2001281267B2 (en) 2001-08-10 2008-05-15 Dynavax Technologies Corporation Immunomodulatory oligonnucleotide formulations and methods for use thereof
CA2492826C (en) 2001-09-14 2016-12-13 Cytos Biotechnology Ag Encapsulation of unmethylated cpg-containing oligonucleotides into virus-like particles: method of preparation and use
US7850990B2 (en) 2001-10-03 2010-12-14 Celator Pharmaceuticals, Inc. Compositions for delivery of drug combinations
US20030134810A1 (en) 2001-10-09 2003-07-17 Chris Springate Methods and compositions comprising biocompatible materials useful for the administration of therapeutic agents
TW200303759A (en) 2001-11-27 2003-09-16 Schering Corp Methods for treating cancer
EP1474396B9 (en) 2002-02-05 2008-07-09 Bristol-Myers Squibb Company N-substituted3-hydroxy-4-pyridinones and pharmaceuticals containing thereof
US8088388B2 (en) 2002-02-14 2012-01-03 United Biomedical, Inc. Stabilized synthetic immunogen delivery system
WO2004014322A2 (en) 2002-08-12 2004-02-19 Dynavax Technologies Corporation Immunomodulatory compositions, methods of making, and methods of use thereof
ZA200503511B (en) 2002-10-29 2006-10-25 Coley Pharmaceutical Group Ltd Use of CPG oligonucleotides in the treatment of hepatitis C virus infection
US20040158051A1 (en) 2002-11-19 2004-08-12 Mihri Ozkan Mono and dual conjugation of nanostructures and methods of making and using thereof
GB0227738D0 (en) 2002-11-28 2003-01-08 Univ Liverpool Nanoparticle conjugates and method of production thereof
US8158768B2 (en) 2002-12-23 2012-04-17 Dynavax Technologies Corporation Immunostimulatory sequence oligonucleotides and methods of using the same
CA2511538C (en) 2002-12-30 2013-11-26 3M Innovative Properties Company Immunostimulatory combinations
US20060105343A1 (en) 2003-01-09 2006-05-18 Children's Medical Center Corporation Methods for diagnosis and prognosis of cancer
US7354907B2 (en) 2003-02-07 2008-04-08 Idera Pharmaceuticals, Inc. Short immunomodulatory oligonucleotides
US7569554B2 (en) 2003-05-16 2009-08-04 Idera Pharmaceuticals, Inc. Synergistic treatment of cancer using immunomers in conjunction with therapeutic agents
ATE441861T1 (de) 2003-05-30 2009-09-15 Nanosphere Inc Verfahren zum nachweis von analyten auf grundlage von evaneszenzbelichtung und auf streuung beruhender nachweis von nanopartikelsondenkomplexen
US7727969B2 (en) 2003-06-06 2010-06-01 Massachusetts Institute Of Technology Controlled release nanoparticle having bound oligonucleotide for targeted delivery
GB0313259D0 (en) 2003-06-09 2003-07-16 Consejo Superior Investigacion Magnetic nanoparticles
EP2371834B1 (en) 2003-06-11 2016-02-17 Idera Pharmaceuticals, Inc. Stabilized immunomodulatory oligonucleotides
US20050096263A1 (en) 2003-10-30 2005-05-05 Keay Susan K. Novel antiproliferative factor and methods of use
JP2009513532A (ja) 2003-07-10 2009-04-02 サイトス バイオテクノロジー アーゲー パッケージ化ウイルス様粒子
US20060074040A1 (en) 2003-07-15 2006-04-06 Hybridon, Inc. Synergistic stimulation of the immune system using immunostimulatory oligonucleotides and/or immunomer compounds in conjunction with cytokines and/or chemotherapeutic agents or radiation therapy
US20080057128A1 (en) 2003-07-18 2008-03-06 Omeros Corporation Biodegradable triblock copolymers, synthesis methods therefore, and hydrogels and biomaterials made there from
JP4690324B2 (ja) 2003-09-09 2011-06-01 ジェロン・コーポレーション テロメラーゼ阻害のための改変オリゴヌクレオチド
US7615539B2 (en) 2003-09-25 2009-11-10 Coley Pharmaceutical Group, Inc. Nucleic acid-lipophilic conjugates
US7846412B2 (en) 2003-12-22 2010-12-07 Emory University Bioconjugated nanostructures, methods of fabrication thereof, and methods of use thereof
EP1550458A1 (en) 2003-12-23 2005-07-06 Vectron Therapeutics AG Synergistic liposomal adjuvants
EP1547581A1 (en) 2003-12-23 2005-06-29 Vectron Therapeutics AG Liposomal vaccine for the treatment of human hematological malignancies
US7959659B2 (en) 2004-01-02 2011-06-14 Advanced Cardiovascular Systems, Inc. High-density lipoprotein coated medical devices
NZ549643A (en) 2004-02-26 2009-07-31 Layerlab Aktiebolag Methods of forming lipid membrane attached linkers comprising contacting membrane with an oligonucleotide having two or more hydrophobic anchoring moieties
WO2005111057A2 (en) 2004-04-02 2005-11-24 Coley Pharmaceutical Group, Inc. Immunostimulatory nucleic acids for inducing il-10 responses
WO2005108614A2 (en) 2004-04-07 2005-11-17 Northwestern University Reversible and chemically programmable micelle assembly with dna block-copolymer amphiphiles
GB0409940D0 (en) 2004-05-04 2004-06-09 Glaxosmithkline Biolog Sa Vaccine
US20080305106A1 (en) 2004-05-12 2008-12-11 Jane Brennan Novel Gene Disruptions, Composition and Methods Relating Thereto
GB0411537D0 (en) 2004-05-24 2004-06-23 Midatech Ltd Nanoparticles comprising rna ligands
EP2330208B1 (en) 2004-05-24 2017-10-18 Midatech Ltd. Nanoparticles comprising RNA ligands
AU2005287383B2 (en) 2004-05-25 2011-09-22 Chimeros, Inc. Self-assembling nanoparticle drug delivery system
EP1604669A1 (en) 2004-06-10 2005-12-14 Institut National De La Sante Et De La Recherche Medicale (Inserm) Use of ATP analogues for treatment of cardiovascular diseases
US7498425B2 (en) 2004-06-15 2009-03-03 Idera Pharmaceuticals, Inc. Immunostimulatory oligonucleotide multimers
RU2007101039A (ru) 2004-06-15 2008-07-20 Айдера Фармасьютикалз Иммуностимулирующие олигонуклеотидные мультимеры
WO2006012695A1 (en) 2004-08-04 2006-02-09 Panvax Limited An immunogenic composition
WO2006015560A1 (de) 2004-08-09 2006-02-16 Mologen Ag Immunmodulierendes mittel in verbindung mit chemotherapeutischen massnahmen
WO2006044660A2 (en) 2004-10-14 2006-04-27 Vanderbilt University Functionalized solid lipid nanoparticles and methods of making and using same
MY159370A (en) 2004-10-20 2016-12-30 Coley Pharm Group Inc Semi-soft-class immunostimulatory oligonucleotides
AU2005304771A1 (en) 2004-11-09 2006-05-18 University Of Southern California Targeted innate immunity
ATE521621T1 (de) 2004-11-29 2011-09-15 Changchun Huapu Biotechnology Co Ltd Cpg-einzelstrang-desoxynukleotide zur verwendung als adjuvans
EP1674128A1 (en) 2004-12-22 2006-06-28 Steinbeis-Transferzentrum für Herz-Kreislaufforschung Magnetic pole matrices useful for tissue engineering and treatment of disease
US8007829B2 (en) 2005-01-19 2011-08-30 William Marsh Rice University Method to fabricate inhomogeneous particles
KR100704011B1 (ko) 2005-02-16 2007-04-04 한국과학기술원 금속나노입자와 양자점의 ｆｒｅｔ에 의한 생체분자특이결합 검출 방법
SG160336A1 (en) 2005-03-04 2010-04-29 Dynavax Tech Corp Vaccines comprising oligonucleotides having immunostimulatory sequences (iss) wherein the iss are conjugated to antigens and stabilized by buffer conditions and further excipients
JP2008538280A (ja) 2005-03-29 2008-10-23 ザ・ボード・オブ・トラスティーズ・オブ・ザ・レランド・スタンフォード・ジュニア・ユニバーシティ 脂質二分子膜の製造方法
US8246995B2 (en) 2005-05-10 2012-08-21 The Board Of Trustees Of The Leland Stanford Junior University Hydrophobic nanotubes and nanoparticles as transporters for the delivery of drugs into cells
CA2912259C (en) 2005-05-27 2020-04-28 Mark H. Schoenfisch Nitric oxide-releasing particles for nitric oxide therapeutics and biomedical applications
US8252756B2 (en) 2005-06-14 2012-08-28 Northwestern University Nucleic acid functionalized nanoparticles for therapeutic applications
JP2009500412A (ja) 2005-07-07 2009-01-08 コーリー ファーマシューティカル グループ，インコーポレイテッド 癌の処置のための、抗ｃｔｌａ−４抗体とｃｐｇモチーフ含有合成オリゴデオキシヌクレオチドとの組み合わせ治療
US8067571B2 (en) 2005-07-13 2011-11-29 Avi Biopharma, Inc. Antibacterial antisense oligonucleotide and method
US20090221095A1 (en) 2005-10-13 2009-09-03 Northwestern University Colorimetric Screening of DNA Binding/Intercalating Agents with Gold Nanoparticle Probes
FR2892819B1 (fr) 2005-10-28 2008-02-01 Centre Nat Rech Scient Nanoparticules a luminescence persistance pour leur utilisation en tant qu'agent de diagnostic destine a l'imagerie optique in vivo
CA2632797A1 (en) 2005-12-01 2007-06-07 The Provost, Fellows And Scholars Of The College Of The Holy And Undivid Ed Trinity Of Queen Elizabeth Near Dublin Compositions and methods relating to treatment of cancer and infectious diseases using toll like receptor agonists
US20090317802A1 (en) 2005-12-09 2009-12-24 Bhatia Sangeeta N Compositions and Methods to Monitor RNA Delivery to Cells
US20070184068A1 (en) 2005-12-14 2007-08-09 Cytos Biotechnology Ag Immunostimulatory nucleic acid packaged particles for the treatment of hypersensitivity
US20070148251A1 (en) 2005-12-22 2007-06-28 Hossainy Syed F A Nanoparticle releasing medical devices
EP1979488A4 (en) 2006-01-09 2009-05-27 Univ California IMMUNOSTIMULATING COMBINATIONS OF TNFRSF, TLR, NLR, RHR, PURINERIC RECEPTOR, AND CYTOKIN RECEPTOR ANTONISTS FOR VACCINES AND TUMOR IMMUNOTHERAPY
AU2007212700A1 (en) 2006-01-26 2007-08-16 University Of Massachusetts RNA interference agents for therapeutic use
US7723045B2 (en) 2006-02-10 2010-05-25 The Regents Of The University Of California Assays to predict atherosclerosis and dysfunctional high-density lipoprotein
PT1991678E (pt) 2006-02-15 2015-11-25 Adiutide Pharmaceuticals Gmbh Composições e métodos para formulações de oligonucleótidos
EP1820804A1 (en) 2006-02-20 2007-08-22 Humboldt-Universität zu Berlin Lipidated oligonucleotides
US8361494B2 (en) 2006-03-10 2013-01-29 The Trustees Of The University Of Pennsylvania Biomimetic iron-oxide-containing lipoprotein and related materials
US20100167051A1 (en) 2006-03-31 2010-07-01 Goia Dan V Process for Manufacture of Silver-Based Particles and Electrical Contact Materials
GB0607866D0 (en) 2006-04-20 2006-05-31 Isis Innovation Nanostructures
EA017860B1 (ru) 2006-05-11 2013-03-29 Мологен Аг Мультимер для иммуностимуляции
WO2007137117A2 (en) 2006-05-17 2007-11-29 Massachusetts Institute Of Technology Aptamer-directed drug delivery
US8748567B2 (en) 2006-05-22 2014-06-10 Children's Medical Center Corporation Method for delivery across the blood brain barrier
US20090280188A1 (en) 2006-06-23 2009-11-12 Northwestern University Asymmetric functionalizated nanoparticles and methods of use
US8017237B2 (en) 2006-06-23 2011-09-13 Abbott Cardiovascular Systems, Inc. Nanoshells on polymers
AU2007280690C1 (en) 2006-07-31 2012-08-23 Curevac Gmbh Nucleic acid of formula (I): GIXmGn, or (II): CIXmCn, in particular as an immune-stimulating agent/adjuvant
US20080124366A1 (en) 2006-08-06 2008-05-29 Ohlfest John R Methods and Compositions for Treating Tumors
CN101652126B (zh) 2006-08-08 2013-07-17 得克萨斯大学体系董事会 活性试剂的多级递送
US20090035576A1 (en) 2006-09-08 2009-02-05 Prasad Paras N Nanoparticles for two-photon activated photodynamic therapy and imaging
SI2468300T1 (en) 2006-09-26 2018-03-30 Infectios Disease Research Institute A vaccine composition comprising a synthetic adjuvant
US20100099858A1 (en) 2006-09-28 2010-04-22 Mirkin Chad A Maximizing Oligonucleotide Loading on Gold Nanoparticle
ITFI20060263A1 (it) 2006-10-27 2008-04-28 Saeco Ipr Ltd Dispositivo emulsionatore per la produzione di latte schiumato e simili e relativo metodo
US20080181928A1 (en) 2006-12-22 2008-07-31 Miv Therapeutics, Inc. Coatings for implantable medical devices for liposome delivery
US8415461B2 (en) 2007-01-19 2013-04-09 The Board Of Trustees Of The University Of Illinois Amphiphilic substances and functionalized lipid vesicles including the same
EP2111218B1 (en) 2007-01-24 2014-07-02 Syddansk Universitet Dna controlled assembly of lipid membranes
CA2691066C (en) 2007-02-09 2018-07-31 Northwestern University Particles for detecting intracellular targets
AU2008239495A1 (en) 2007-02-27 2008-10-23 Northwestern University Molecule attachment to nanoparticles
WO2008120736A1 (ja) 2007-03-30 2008-10-09 Otsuka Pharmaceutical Co., Ltd. 薬物送達制御用経肺投与リポソーム
WO2008124639A2 (en) 2007-04-04 2008-10-16 Massachusetts Institute Of Technology Poly (amino acid) targeting moieties
US20100234579A1 (en) 2007-05-10 2010-09-16 North Western University Silver nanoparticle binding agent conjugates based on moieties with triple cyclic disulfide anchoring groups
DK2826863T3 (en) 2007-05-30 2017-12-04 Univ Northwestern NUCLEIC ACID FUNCTIONALIZED NANOPARTICLES FOR THERAPEUTIC APPLICATIONS
CN101765423B (zh) 2007-05-31 2014-08-06 安特里奥公司 核酸纳米粒子和其用途
WO2009045579A2 (en) 2007-06-14 2009-04-09 The Regents Of The University Of California Multimodal imaging probes for in vivo targeted and non-targeted imaging and therapeutics
US20080317768A1 (en) 2007-06-21 2008-12-25 Boeing Company Bioconjugated nanoparticles
US20100272813A1 (en) 2007-07-23 2010-10-28 Aarhus Universitet Nanoparticle-mediated treatment for inflammatory diseases
US8563527B2 (en) 2007-08-20 2013-10-22 Pharmain Corporation Oligonucleotide core carrier compositions for delivery of nucleic acid-containing therapeutic agents, methods of making and using the same
JP5484339B2 (ja) 2007-10-05 2014-05-07 ウェイン ステート ユニバーシティー 合成物の持続的な放出のためのデンドリマー
EP2209472A1 (en) 2007-10-12 2010-07-28 The University of North Carolina at Chapel Hill Use of nitric oxide to enhance the efficacy of silver and other topical wound care agents
EP2217221B1 (en) 2007-10-17 2018-06-27 Korea Advanced Institute of Science and Technology Ldl-like cationic nanoparticles for deliverying nucleic acid gene, method for preparing thereof and method for deliverying nucleic acid gene using the same
WO2009061515A1 (en) 2007-11-09 2009-05-14 Northeastern University Self-assembling micelle-like nanoparticles for systemic gene delivery
US9265729B2 (en) 2007-12-06 2016-02-23 The University Of Tokushima Nanofunctional silica particles and manufacturing method thereof
US20090148384A1 (en) 2007-12-10 2009-06-11 Fischer Katrin Functionalized, solid polymer nanoparticles comprising epothilones
WO2009073984A1 (en) 2007-12-12 2009-06-18 University Health Network High-density lipoprotein-like peptide-phospholipid scaffold ('hpps') nanoparticles
WO2009089115A1 (en) 2008-01-04 2009-07-16 Hormel Foods Corporation Encapsulation of oxidatively unstable compounds
JP2011518116A (ja) 2008-02-21 2011-06-23 ユニバーシティ オブ ケンタッキー リサーチ ファウンデーション トール様受容体３拮抗薬としての超小型ｒｎａ
EP2259798B1 (en) 2008-03-05 2013-12-11 Baxter International Inc. Surface-modified particles and methods for targeted drug delivery
CA2719614C (en) 2008-03-25 2018-05-01 Juvaris Biotherapeutics, Inc. Enhancement of an immune response by administration of a cationic lipid-dna complex (cldc)
EP2105145A1 (en) 2008-03-27 2009-09-30 ETH Zürich Method for muscle-specific delivery lipid-conjugated oligonucleotides
BRPI0907260A2 (pt) 2008-04-21 2015-07-14 3M Innovative Properties Co "métodos, dispositivos e composições que liberam óxido nítrico"
WO2009131704A2 (en) 2008-04-25 2009-10-29 Northwestern University Nanostructures suitable for sequestering cholesterol and other molecules
US20110280930A1 (en) 2008-05-02 2011-11-17 Facundo Batista Products and methods for stimulating an immune response
US8268796B2 (en) 2008-06-27 2012-09-18 Children's Hospital & Research Center At Oakland Lipophilic nucleic acid delivery vehicle and methods of use thereof
US20100047188A1 (en) 2008-08-04 2010-02-25 Idera Pharmaceuticals, Inc. Modulation of toll-like receptor 8 expression by antisense oligonucleotides
AU2009279857A1 (en) 2008-08-04 2010-02-11 Idera Pharmaceuticals, Inc. Modulation of toll-like receptor 3 expression by antisense oligonucleotides
KR20110050531A (ko) 2008-08-28 2011-05-13 글락소스미스클라인 바이오로지칼즈 에스.에이. 백신
WO2010037402A1 (en) 2008-10-02 2010-04-08 Dako Denmark A/S Molecular vaccines for infectious disease
NZ601345A (en) 2008-10-16 2014-05-30 Univ Dalhousie Combination adjuvant formulation
US8574582B2 (en) 2008-10-31 2013-11-05 Janssen Biotech, Inc. Methods for mediating fibrotic response
WO2010060104A2 (en) 2008-11-24 2010-05-27 Moma Therapeutics Implantable liposome embedded matrix composition, uses thereof, and polycaprolactone praticles as scaffolds for tissue regeneration
US9139827B2 (en) 2008-11-24 2015-09-22 Northwestern University Polyvalent RNA-nanoparticle compositions
CN102333538B (zh) 2008-12-09 2014-01-15 科勒制药集团有限公司 免疫刺激性寡核苷酸
US8298765B2 (en) 2009-01-01 2012-10-30 Cornell University Multifunctional nucleic acid nano-structures
MX2011007350A (es) 2009-01-08 2011-09-06 Univ Northwestern Inhibicion de produccion de proteina bacteriana por conjugados de nanoparticulas modificadas por oligonucleotidos polivalentes.
US20100233270A1 (en) 2009-01-08 2010-09-16 Northwestern University Delivery of Oligonucleotide-Functionalized Nanoparticles
WO2010088395A2 (en) 2009-01-30 2010-08-05 Idera Pharmaceuticals, Inc. Novel synthetic agonists of tlr9
WO2010091293A1 (en) 2009-02-06 2010-08-12 The Regents Of The University Of California Plasmonic system for detecting binding of biological molecules
AR070368A2 (es) 2009-02-12 2010-03-31 Smithkline Beecham Biolog Procedimiento para la preparacion de una composicion de vacuna que comprende un inmunoestimulante un antigeno y una sal metalica y uso de dicha composicion para preparar un medicamento.composicion de vacuna
CA2754043A1 (en) 2009-03-12 2010-09-16 Alnylam Pharmaceuticals, Inc. Lipid formulated compositions and methods for inhibiting expression of eg5 and vegf genes
CN102625842A (zh) 2009-03-13 2012-08-01 艾根股份有限公司 用于输送生物活性rna的组合物和方法
AU2010237001B2 (en) 2009-04-15 2016-07-07 Northwestern University Delivery of oligonucleotide-functionalized nanoparticles
CA2763832A1 (en) 2009-05-29 2010-12-02 Envision Scientific Private Limited Re-establishment of blood flow in blocked human arteries by transferring nano-encapsulated drug through medical devices, designed for the same and releasing the nano-encapsulated drug in human artery with body ph
JP5707396B2 (ja) 2009-06-17 2015-04-30 アイシス ファーマシューティカルズ， インコーポレーテッド 被験体におけるｓｍｎ２スプライシングのモジュレーションのための組成物および方法
KR101626060B1 (ko) 2009-06-18 2016-05-31 한림대학교 산학협력단 리포좀에 포집된 올리고뉴클레오타이드를 유효성분으로 하는 면역증강 조성물
CN103977394B (zh) 2009-07-17 2016-03-09 翰林大学校产学协力团 包含脂质体包胶的寡核苷酸和表位的免疫刺激性组合物
WO2011017382A2 (en) 2009-08-03 2011-02-10 The Regents Of The University Of California Nanofibers and morphology shifting micelles
US20120277283A1 (en) 2009-08-04 2012-11-01 Mirkin Chad A Localized Delivery of Gold Nanoparticles for Therapeutic and Diagnostic Applications
WO2011017690A2 (en) 2009-08-07 2011-02-10 Northwestern University Intracellular delivery of contrast agents with functionalized nanoparticles
WO2011028850A1 (en) 2009-09-01 2011-03-10 Northwestern University Delivery of therapeutic agents using oligonucleotide-modified nanoparticles as carriers
WO2011028847A1 (en) 2009-09-01 2011-03-10 Northwestern University Polyvalent polynucleotide nanoparticle conjugates as delivery vehicles for a chemotherapeutic agent
US20110053829A1 (en) 2009-09-03 2011-03-03 Curevac Gmbh Disulfide-linked polyethyleneglycol/peptide conjugates for the transfection of nucleic acids
WO2011037973A1 (en) 2009-09-23 2011-03-31 Northwestern University "click" nanoparticle conjugates
US20110111974A1 (en) 2009-10-23 2011-05-12 Northwestern University Short Duplex Probes for Enhanced Target Hybridization
US9138418B2 (en) 2009-12-09 2015-09-22 William Marsh Rice University Therapeutic compositions and methods for delivery of active agents cleavably linked to nanoparticles
SG181823A1 (en) 2009-12-23 2012-07-30 Max Planck Gesellschaft Influenza targets
US20130178610A1 (en) 2009-12-24 2013-07-11 Chad A. Mirkin Oligonucleotide specific uptake of nanoconjugates
US20130034599A1 (en) 2010-01-19 2013-02-07 Northwestern University Synthetic nanostructures including nucleic acids and/or other entities
EP2399608B1 (en) 2010-03-05 2020-07-08 Sebastian Fuchs Immunomodulating nanoparticulate composition for use in inhalation therapy
WO2011113054A2 (en) 2010-03-12 2011-09-15 Aurasense Llc Crosslinked polynucleotide structure
EP2555802A1 (en) 2010-04-08 2013-02-13 Sanford-Burnham Medical Research Institute Methods and compositions for enhanced delivery of compounds
US9169325B2 (en) 2010-04-13 2015-10-27 Celldex Therapeutics, Inc. Antibodies that bind human CD27 and uses thereof
CA2798074A1 (en) 2010-04-27 2011-11-03 The Johns Hopkins University Immunogenic compositions and methods for treating neoplasia
KR101198715B1 (ko) 2010-05-14 2012-11-13 한국생명공학연구원 핵산 및 친수성 음이온 화합물의 고효율 포획을 위한 비대칭 리포솜 및 이의 제조방법
CN105194665A (zh) 2010-05-26 2015-12-30 西莱克塔生物科技公司 具有不偶合的佐剂的纳米载体组合物
RS57428B1 (sr) 2010-05-28 2018-09-28 Zoetis Belgium S A Vakcine koje sadrže holesterol i cpg kao jedine molekule nosače ađuvansa
US20130089614A1 (en) 2010-06-14 2013-04-11 Xuefeng Zhang Magnetic Nanoparticles and Uses Thereof
WO2012006634A2 (en) 2010-07-09 2012-01-12 The Board Of Trustees Of The University Of Illiniois Prostate specific antigen (psa) peptide therapy
CN107648604A (zh) 2010-07-30 2018-02-02 库瑞瓦格股份公司 聚合物载体运载物复合物及聚合物载体的用途
US9549901B2 (en) 2010-09-03 2017-01-24 The Brigham And Women's Hospital, Inc. Lipid-polymer hybrid particles
US20130095039A1 (en) 2010-09-30 2013-04-18 The Board Of Trustees Of The University Of Illinois Nucleic acid-mediated shape control of nanoparticles
WO2012055933A1 (en) 2010-10-26 2012-05-03 Ac Immune S.A. Liposome-based construct comprising a peptide modified through hydrophobic moieties
WO2012084991A1 (en) 2010-12-21 2012-06-28 Index Pharmaceuticals Ab Biologically active oligonucleotides capable of modulating the immune system ii
US9999673B2 (en) 2011-01-11 2018-06-19 Alnylam Pharmaceuticals, Inc. PEGylated lipids and their use for drug delivery
US9675561B2 (en) 2011-04-28 2017-06-13 President And Fellows Of Harvard College Injectable cryogel vaccine devices and methods of use thereof
WO2012177624A2 (en) 2011-06-21 2012-12-27 The Johns Hopkins University Focused radiation for augmenting immune-based therapies against neoplasms
WO2013009701A2 (en) 2011-07-08 2013-01-17 The University Of North Carolina At Chapel Hill Metal bisphosphonate nanoparticles for anti-cancer therapy and imaging and for treating bone disorders
WO2013012628A2 (en) * 2011-07-15 2013-01-24 The University Of Georgia Research Foundation, Inc. Immune-stimulating photoactive hybrid nanoparticles
EP2548571A1 (en) 2011-07-22 2013-01-23 Institut Curie Compositions having means for targeting at least one antigen to dendritic cells
CA2843274A1 (en) 2011-07-29 2013-02-07 Selecta Biosciences, Inc. Synthetic nanocarriers that generate humoral and cytotoxic t lymphocyte (ctl) immune responses
WO2013033513A1 (en) 2011-08-31 2013-03-07 University Of Georgia Research Foundation, Inc. Apoptosis-targeting nanoparticles
WO2013036974A1 (en) * 2011-09-11 2013-03-14 Aurasense, Llc Cellular uptake control systems
US9308253B2 (en) 2011-09-19 2016-04-12 The Johns Hopkins University Cancer immunotherapy
US20130071403A1 (en) 2011-09-20 2013-03-21 Vical Incorporated Synergistic anti-tumor efficacy using alloantigen combination immunotherapy
IN2014CN02581A (cg-RX-API-DMAC7.html) 2011-10-06 2015-08-07 Immunovaccine Technologies Inc
CA2858336A1 (en) 2012-01-01 2013-07-04 Qbi Enterprises Ltd. Endo180-targeted particles for selective delivery of therapeutic and diagnostic agents
WO2013113326A1 (en) 2012-01-31 2013-08-08 Curevac Gmbh Pharmaceutical composition comprising a polymeric carrier cargo complex and at least one protein or peptide antigen
ES2664725T3 (es) 2012-02-17 2018-04-23 Mayo Foundation For Medical Education And Research Métodos y materiales para generar células T CD8+ con la capacidad para reconocer células cancerígenas que expresen un polipéptido HER2/neu
US20150064255A1 (en) 2012-02-22 2015-03-05 Northwestern University Nanostructures for treating cancers and other conditions
EP3563872A1 (en) 2012-04-05 2019-11-06 Massachusetts Institute Of Technology Immunostimulatory compositions and methods of use thereof
SG10201603896RA (en) 2012-05-04 2016-07-28 Pfizer Prostate-associated antigens and vaccine-based immunotherapy regimens
MX353567B (es) 2012-05-23 2018-01-18 Univ Ohio State Composiciones de nanoparticulas de lipidos para la entrega de oligonucleotidos antisentido.
BR112015000723A2 (pt) 2012-07-13 2017-06-27 Shin Nippon Biomedical Laboratories Ltd adjuvante de ácido nucléico quiral
CN103566377A (zh) 2012-07-18 2014-02-12 上海博笛生物科技有限公司 癌症的靶向免疫治疗
US9931418B2 (en) 2012-08-07 2018-04-03 Northeastern University Compositions for the delivery of RNA and drugs into cells
US9095625B2 (en) 2012-08-31 2015-08-04 University Of Massachusetts Graft-copolymer stabilized metal nanoparticles
WO2014120379A1 (en) 2013-01-31 2014-08-07 Privail Inc. Testing device
KR20150132131A (ko) 2013-02-05 2015-11-25 1글로브 헬스 인스티튜트 엘엘씨 약물 전달 담체로서 생체분해가능하고 임상적으로 상용가능한 나노입자
US9968673B2 (en) 2013-02-26 2018-05-15 Commissariat á l'ènergie atomique et aux ènergies alternatives Immunogenic composition in emulsion form comprising two dispersed phases, one comprising an antigen and the other comprising an immunostimulating agent
EP2961395B1 (en) 2013-03-01 2024-06-19 California Institute Of Technology Targeted nanoparticles
EP2970369B1 (en) 2013-03-14 2023-11-22 TheraSyn Sensors, Inc. Cholestosome vesicles for incorporation of molecules into chylomicrons
CN103212089B (zh) * 2013-04-07 2016-08-24 中国科学院上海应用物理研究所 一种碳纳米材料-免疫刺激序列复合物的制备方法及其应用
WO2014169264A2 (en) 2013-04-11 2014-10-16 The Board Of Trustees Of The University Of Illinois Nanoparticle mediated delivery of sirna
AR095882A1 (es) 2013-04-22 2015-11-18 Hoffmann La Roche Terapia de combinación de anticuerpos contra csf-1r humano con un agonista de tlr9
WO2014201245A1 (en) 2013-06-12 2014-12-18 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Tlr-9 agonist with tlr-7 and/or tlr-8 agonist for treating tumors
AU2014292926B2 (en) * 2013-07-25 2020-03-05 Exicure Operating Company Spherical nucleic acid-based constructs as immunostimulatory agents for prophylactic and therapeutic use
WO2015013675A1 (en) 2013-07-25 2015-01-29 Aurasense Therapeutics, Llc Spherical nucleic acid-based constructs as immunoregulatory agents
JP6527516B2 (ja) 2013-12-03 2019-06-05 ノースウェスタン ユニバーシティ リポソーム粒子、前述のものを作製する方法及びその使用
WO2015108047A1 (ja) 2014-01-15 2015-07-23 株式会社新日本科学 免疫誘導活性を有するキラル核酸アジュバンド及び免疫誘導活性剤
GB2523187A (en) 2014-02-18 2015-08-19 Mologen Ag Covalently closed non-coding immunomodulatory DNA construct
EP3129391A4 (en) 2014-04-03 2017-12-20 Exicure, Inc. Self assembling nucleic acid nanostructures
WO2015187966A1 (en) 2014-06-04 2015-12-10 Aurasense Therapeutics, Llc Multivalent delivery of immune modulators by liposomal spherical nucleic acids for prophylactic or therapeutic applications
TW201620526A (zh) 2014-06-17 2016-06-16 愛羅海德研究公司 用於抑制α－１抗胰蛋白酶基因表現之組合物及方法
WO2016004168A1 (en) 2014-07-01 2016-01-07 Aurasense Therapeutics, Llc Spherical nanoparticles as antibacterial agents
BR112017007012A2 (pt) 2014-10-06 2018-03-06 Exicure Inc compostos anti-tnf
JP6991857B2 (ja) 2014-10-10 2022-01-13 イデラ ファーマシューティカルズ インコーポレイテッド Ｔｌｒ９アゴニストをチェックポイント阻害剤と共に用いるがんの治療
CA2973702A1 (en) 2015-01-14 2016-07-21 Exicure, Inc. Nucleic acid nanostructures with core motifs
US20180042848A1 (en) 2015-02-18 2018-02-15 Exicure, Inc. Immuno-regulatory lipid containing spherical nucleic acids
WO2016149323A1 (en) 2015-03-16 2016-09-22 Exicure, Inc. Immunomodulatory spherical nucleic acids
US10078092B2 (en) 2015-03-18 2018-09-18 Northwestern University Assays for measuring binding kinetics and binding capacity of acceptors for lipophilic or amphiphilic molecules
AU2016294594A1 (en) 2015-07-14 2018-02-08 Exicure, Inc. Spherical nucleic acid (SNA)-mediated delivery of lipid-complexes to cells
US10426842B2 (en) 2015-07-15 2019-10-01 The Curators Of The University Of Missouri Targeted nanoparticle conjugate and method for co-delivery of siRNA and drug
EP3340967B1 (en) 2015-08-24 2024-05-22 Halo-Bio Rnai Therapeutics, Inc. Polynucleotide nanoparticles for the modulation of gene expression and uses thereof
LU92821B1 (en) 2015-09-09 2017-03-20 Mologen Ag Combination comprising immunostimulatory oligonucleotides
US20190142739A1 (en) 2016-04-19 2019-05-16 Exicure, Inc. Topical administration of therapeutic agents and oligonucleotide formulations
WO2017193087A1 (en) 2016-05-06 2017-11-09 Exicure, Inc. Liposomal spherical nucleic acid (sna) constructs prsenting antisense oligonucleotides(aso) for specific knockdown of interleukin 17 receptor mrna
AU2017261354A1 (en) 2016-05-06 2018-11-29 Exicure Operating Company Spherical Nucleic Acid TLR9 agonists
EP4559479A3 (en) 2016-08-30 2025-06-11 Dana-Farber Cancer Institute, Inc. Drug delivery compositions and uses thereof
CA3036978A1 (en) 2016-09-15 2018-03-22 Idera Pharmaceuticals, Inc. Immune modulation with tlr9 agonists for cancer treatment
US20190374650A1 (en) 2017-02-22 2019-12-12 The Regents Of The University Of Michigan Compositions and methods for delivery of polymer/biomacromolecule conjugates
WO2018201090A1 (en) 2017-04-28 2018-11-01 Exicure, Inc. Synthesis of spherical nucleic acids using lipophilic moieties
WO2019168558A1 (en) 2018-02-28 2019-09-06 Exicure, Inc. Liposomal spherical nucleic acid (sna) constructs for survival of motor neuron (sma) inhibitors
US20210002640A1 (en) 2018-02-28 2021-01-07 Exicure, Inc. Liposomal spherical nucleic acid (sna) constructs for survival of motor neuron (sma) inhibitors

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120282186A1 (en) * 2009-10-30 2012-11-08 Northwestern University Templated nanoconjugates

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ADAM YUH LIN ET AL, PLOS ONE, (2013-05-15), vol. 8, no. 5, doi:10.1371/journal.pone.0063550, ISSN 1932-6203, page e63550 *

Also Published As

Publication number Publication date
CN105579582A (zh) 2016-05-11
EP3024936B1 (en) 2019-09-04
CA2919268C (en) 2023-09-05
CA2919268A1 (en) 2015-01-29
US20180320184A1 (en) 2018-11-08
US20160186178A1 (en) 2016-06-30
AU2014292926A1 (en) 2016-03-10
WO2015013673A1 (en) 2015-01-29
JP6697384B2 (ja) 2020-05-20
US10894963B2 (en) 2021-01-19
JP2016530879A (ja) 2016-10-06
US10837018B2 (en) 2020-11-17
KR20160042917A (ko) 2016-04-20
US20210102211A1 (en) 2021-04-08
US20250283096A1 (en) 2025-09-11
EP3024936A1 (en) 2016-06-01
ES2750608T3 (es) 2020-03-26

Similar Documents

Publication Publication Date Title
US20250283096A1 (en) Spherical nucleic acid-based constructs as immunostimulatory agents for prophylactic and therapeutic use
US11957788B2 (en) Multivalent delivery of immune modulators by liposomal spherical nucleic acids for prophylactic or therapeutic applications
US20160194642A1 (en) Spherical nucleic acid-based constructs as immunoregulatory agents
US20170175121A1 (en) Self assembling nucleic acid nanostructures
EP1928500A2 (en) Modulation of tlr-mediated immune responses using adaptor oligonucleotides
KR20100045508A (ko) 특이적 면역 조절 프로필을 유도하는 규정된 뉴클레오티드간 연결의 환경에서의 ｒｎａ 서열 모티프

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
PC Assignment registered

Owner name: EXICURE OPERATING COMPANY

Free format text: FORMER OWNER(S): EXICURE, INC.